Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,004 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Adult Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects

NCT02253342
View directory record Official record
Conditions
Intrapulmonary Pharmacokinetics of WCK 2349
Interventions
WCK-2349
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

NCT06050291
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Fixed-Dose Combination (FDC) Tablet
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

NCT04528290
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 8, 2026, 9:12 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

NCT07117383
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
ASP-001.1, ASP-001, Commercial Sildenafil and Sildenafil/Tadalafil Products
Device · Drug
Lead sponsor
Aspargo Labs, Inc
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions

NCT00829673
View directory record Official record
Conditions
Healthy
Interventions
Dexmethylphenidate Hydrochloride
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RDEA3170 Bioavailability Study

NCT02336594
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 10 mg, RDEA3170 2.5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

NCT02039765
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine tartrate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

NCT01967771
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, CBZ
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

NCT00490945
View directory record Official record
Conditions
Circadian Rhythm Sleep Disorders
Interventions
VEC-162
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01506570
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

NCT03803202
View directory record Official record
Conditions
Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
Interventions
ASP3772, PCV13, PPSV23
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
26
States / cities
Banning, California • San Diego, California • San Marcos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

NCT06570369
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Healthy
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Garden Grove, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

NCT06937619
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Anaheim, California • Los Alamitos, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults

NCT02044081
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Rinse, Placebo, C16G2 Gel
Drug
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Kalispell, Montana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

NCT05325346
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
VLX-1005, Argatroban
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

NCT01243151
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
9
States / cities
Culver City, California • Glendale, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

NCT01611467
View directory record Official record
Conditions
Safety and Pharmacokinetics in Healthy Volunteer Subjects
Interventions
CC-223
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of [14C]-LOXO-783 in Healthy Adult Participants

NCT06102512
View directory record Official record
Conditions
Healthy
Interventions
[¹⁴C]-LOXO-783, LOXO-783
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

NCT04839809
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-92480, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT05567393
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951 Placebo, TAK-951
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Nebulized RNS60 to Treat Asthma.

NCT01057498
View directory record Official record
Conditions
Asthma
Interventions
RNS60, RNS60 - single dose
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Cypress, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects

NCT02500667
View directory record Official record
Conditions
Drug Interaction Potentiation
Interventions
N91115, Rifampin
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 8, 2026, 9:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

NCT01476800
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of YM178
Interventions
YM178 OCAS, Ketoconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Sep 8, 2026, 9:12 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants

NCT07599761
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722, Itraconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 8, 2026, 9:12 AM EDT